Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Advances in biomarkers of benzene exposure and toxicity: From mechanistic insights to occupational health applications (Review).

Created on 25 Sep 2026

Authors

Yuanshe Huang, Zhenjun Xi, Jingxin Mao, Xiaobing Li

Published in

Molecular medicine reports. Volume 34. Issue 5. Epub Sep 25, 2026.

Abstract

Benzene is a toxic aromatic hydrocarbon widely used in industrial production, posing a notable occupational health threat. Classified as a Group 1 carcinogen, chronic benzene exposure primarily targets the hematopoietic system, causing leukopenia, thrombocytopenia, aplastic anemia and acute myeloid leukemia. Furthermore, emerging evidence highlights its multi‑systemic toxicity, inducing oxidative stress, DNA damage and cellular dysfunction, across the nervous, respiratory, dermatological, reproductive, immune and cardiovascular systems. The present review systematically summarizes recent advances in these occupational hazards and the evolving landscape of benzene biomonitoring. Traditional exposure biomarkers, such as urinary phenol and hydroquinone, are increasingly being supplemented by highly specific metabolites, notably S‑phenylmercapturic acid, for low‑dose exposure assessments. Effect biomarkers capture early biological damage through hematological indices and molecular alterations, while susceptibility biomarkers, such as cytochrome P450 2E1, glutathione S‑transferase mu 1 and DNA repair gene polymorphisms, identify genetically vulnerable populations. Additionally, emerging non‑invasive tools, particularly exhaled breath metabolomics, show promise in correlating specific metabolites with hematopoietic function. By integrating mechanistic insights into multi‑organ toxicity with advanced multi‑omics profiling, the present review highlights a critical paradigm shift from reactive traditional monitoring to artificial intelligence‑driven, multi-biomarker integration frameworks. Ultimately, it provides a forward-looking roadmap for individualized risk stratification and precision occupational health surveillance in the low‑dose exposure era.

PMID:
42788347
Bibliographic data and abstract were imported from PubMed on 25 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement